NEW YORK, Aug. 7, 2014 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation ("Boston Scientific" or the "Company") (NYSE: BSX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 237.

The investigation concerns whether Boston Scientific and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

On August 6, 2014, Boston Scientific revealed in a U.S. Securities & Exchange Commission ("SEC") filing that it received a subpoena on July 11 from the U.S. Attorney for the District of New Jersey concerning Bridgepoint Medical Inc., a cardiology products company it acquired in October 2012. The subpoena seeks information on sales of CrossBoss and Stingray products as well as related educational and training activities.

On this news, shares of Boston Scientific fell $0.49 per share to $12.36, or more than 3.81%, on August 6, 2014.

The Pomerantz Firm, with offices in New York, Chicago, San Diego and Florida, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 70 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

SOURCE Pomerantz LLP